KIT and lung cancer: Murine lung cancer cells lacking the Mir181ab1 cluster were more sensitive to the multiple–tyrosine kinase (BCR-ABL, SRC, c-KIT) inhibitor dasatinib than those cells in which Mir181ab1 was reconstituted (Figure 8F).